🔗 Share this article

Given that the US proceeds with unprecedented revisions to its vaccine recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning Covid vaccines throughout the global health crisis and has concentrated on possible deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Agency leaders had intended to reveal sweeping changes to the childhood vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth individual to run the division this calendar year.

Consolidating Power at the Agency

The acting appointment might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for halting certain pediatric vaccine recommendations in the US so as to align more like the Danish model, a society with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, approval processes or leadership, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a major agency. She is not an expert in industry regulation.”

Former heads of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an vast portfolio at the agency, she emphasized.

“Everybody just focuses on the new drug program, but the generic program approves a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be looked after,” Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the role, which manages over 5,000 staff members. “It is a massive management job, if you execute it properly,” she said.

Agency Reaction and Disputed Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries are based on incorrect assumptions”.

“Her experience aligns with the functions of her role,” the representative said, noting the period Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a contentious rapid medication authorization process that allegedly worried her former heads. “By what process are these medications being chosen for this voucher program? Who makes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards laxer oversight of pharmaceuticals, aside from immunizations.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts observe. She released a study using unconfirmed public submissions to assess the incidence of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the current government featured changing rules for new vaccines and ending “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested excluding teenage boys from obtaining Covid vaccinations.

“She’s an all-around true believer who begins with her beliefs and reverse-engineers to retrofit the evidence in a very misleading, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|